<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19802386</article-id><article-id pub-id-type="publisher-id">09-PONE-RA-10533R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0007332</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Biochemistry</subject><subject>Cell Biology</subject><subject>Biochemistry/Cell Signaling and Trafficking Structures</subject><subject>Biochemistry/Protein Folding</subject><subject>Cell Biology/Cell Signaling</subject><subject>Cell Biology/Developmental Molecular Mechanisms</subject></subj-group></article-categories><title-group><article-title>COMMD1 Promotes pVHL and O<sub>2</sub>-Independent Proteolysis of HIF-1&#x003b1; via HSP90/70</article-title><alt-title alt-title-type="running-head">COMMD1 Mediates HIF1 Signaling</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van de Sluis</surname><given-names>Bart</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="author-notes" rid="fn1"><sup>&#x000a4;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Groot</surname><given-names>Arjan J.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vermeulen</surname><given-names>Jeroen</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>van der Wall</surname><given-names>Elsken</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Diest</surname><given-names>Paul J.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wijmenga</surname><given-names>Cisca</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Klomp</surname><given-names>Leo W.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vooijs</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Complex Genetics Section, DBG-Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Laboratory for Metabolic and Endocrine Diseases, University Medical Center Utrecht, Utrecht, The Netherlands</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Department of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Department of Pathology and Laboratory Medicine, University Medical Center Groningen, Groningen, The Netherlands</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Rutherford</surname><given-names>Suzannah</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Fred Hutchinson Cancer Research Center, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>m.vooijs@umcutrecht.nl</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: BvdS AJG MV. Performed the experiments: BvdS AJG JV. Analyzed the data: BvdS AJG JV. Contributed reagents/materials/analysis tools: EvdW PvD CW LWK MV. Wrote the paper: BvdS MV.</p></fn><fn id="fn1" fn-type="current-aff"><label>&#x000a4;</label><p>Current address: Department of Pathology and Laboratory Medicine, University Medical Center Groningen, Groningen, The Netherlands</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>5</day><month>10</month><year>2009</year></pub-date><volume>4</volume><issue>10</issue><elocation-id>e7332</elocation-id><history><date date-type="received"><day>18</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>7</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>van de Sluis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>The <underline>C</underline>opper <underline>M</underline>etabolism <underline>M</underline>URR1 <underline>D</underline>omain containing 1 protein COMMD1 has been associated with copper homeostasis, NF-&#x003ba;B signaling, and sodium transport. Recently, we identified COMMD1 as a novel protein in HIF-1 signaling. Mouse embryos deficient for <italic>Commd1</italic> have increased expression of hypoxia/HIF-regulated genes i.e. <italic>VEGF</italic>, <italic>PGK</italic> and <italic>Bnip3</italic>. Hypoxia-inducible factors (HIFs) are master regulators of oxygen homeostasis, which control angiogenesis, erythropoiesis, glycolysis and cell survival/proliferation under normal and pathologic conditions. Although HIF activity is mainly controlled by ubiquitination and protein degradation by the von Hippel Lindau (pVHL) tumor suppressor gene other mechanisms have recently been identified that regulate HIF signaling independently of pVHL.</p></sec><sec><title>Principal Findings</title><p>Here we characterized the mechanism by which COMMD1 regulates HIF-1&#x003b1; protein degradation. We show that COMMD1 competes with the chaperone heat shock protein HSP90&#x003b2; for binding to the NH<sub>2</sub>-terminal DNA-binding and heterodimerization domain of HIF-1&#x003b1; to regulate HIF-1&#x003b1; stability together with HSP70. Inhibition of HSP90 activity with 17-Allylamino-17-demethoxygeldanamycin (17-AAG) increased COMMD1-mediated HIF-1&#x003b1; degradation independent of ubiquitin and pVHL.</p></sec><sec><title>Conclusion/Significance</title><p>These data reveal a novel role for COMMD1 in conjunction with HSP90&#x003b2;/HSP70 in the ubiquitin and O<sub>2</sub>-independent regulation of HIF-1&#x003b1;.</p></sec></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p><underline>Co</underline>pper <underline>M</underline>etabolism <underline>M</underline>URR1 <underline>D</underline>omain 1 protein (COMMD1) is the prototype of the COMMD protein family <xref ref-type="bibr" rid="pone.0007332-Burstein1">&#x0005b;1&#x0005d;</xref>. This family of proteins is highly conserved between eukaryotes, and some members have been identified in protozoa <xref ref-type="bibr" rid="pone.0007332-Burstein1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007332-Maine1">&#x0005b;2&#x0005d;</xref>. The COMM proteins are ubiquitously expressed and characterized by their conserved and distinctive domain (COMM domain) located at the carboxy-terminus. The COMMD domain is important for protein-protein interactions, nuclear export and postranslational modifications of COMMD proteins <xref ref-type="bibr" rid="pone.0007332-Maine2">&#x0005b;3&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007332-Maine3">&#x0005b;5&#x0005d;</xref>.</p><p>To date the best-characterized COMMD protein is COMMD1. We identified COMMD1 (previous called MURR1) to be mutated in dogs with the hepatic copper storage disorder, copper toxicosis <xref ref-type="bibr" rid="pone.0007332-Klomp1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007332-vanDeSluis1">&#x0005b;7&#x0005d;</xref>. Recent observations suggest that COMMD1 regulates the biliary copper excretion via ATP7B, a P-type ATPase copper transporter that is mutated in patients with the copper storage disorder Wilson's disease <xref ref-type="bibr" rid="pone.0007332-deBie1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007332-Tao1">&#x0005b;9&#x0005d;</xref>. It appears that COMMD1 participates in the protein quality control of ATP7B by mediating the proteolysis of ATP7B <xref ref-type="bibr" rid="pone.0007332-deBie1">&#x0005b;8&#x0005d;</xref>.</p><p>COMMD1 also inhibits basal and cytokine induced NF-&#x003ba;B activity by promoting the ubiquitination and proteasomal degradation of RelA <xref ref-type="bibr" rid="pone.0007332-Burstein1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007332-Maine3">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007332-Mao1">&#x0005b;10&#x0005d;</xref>. To understand the <italic>in vivo</italic> role of COMMD1 we generated <italic>Commd1</italic> deficient mice <xref ref-type="bibr" rid="pone.0007332-vandeSluis1">&#x0005b;11&#x0005d;</xref>. Remarkably, <italic>Commd1</italic> knockout mice are embryonically lethal, and show abnormal embryonic development, including placental defects. Gene expression analysis in <italic>Commd1</italic> deficient embryos revealed deregulation of the hypoxia inducible factor (HIF) pathway by upregulation of canonical HIF-1 target genes like <italic>Vegfa</italic>, <italic>Pgk1</italic>, <italic>AldoA</italic>, <italic>Bnip3</italic> and others. Conversely, overexpression of COMMD1 resulted in downregulation of HIF-1 activity <xref ref-type="bibr" rid="pone.0007332-vandeSluis1">&#x0005b;11&#x0005d;</xref>.</p><p>HIF-1 is a key factor in oxygen homeostasis. Under conditions of chronic or acute oxygen deprivation (hypoxia), HIF-1 regulates the transcriptional activation of target genes involved in angiogenesis, erythropoiesis, glycolysis and cell survival/proliferation <xref ref-type="bibr" rid="pone.0007332-Semenza1">&#x0005b;12&#x0005d;</xref>. HIF-1&#x003b1; is a basic-helix-loop-helix (bHLH)-PAS (Per, ARNT, SIM) protein and forms together with HIF-1&#x003b2; the transcription factor HIF-1 <xref ref-type="bibr" rid="pone.0007332-Wang1">&#x0005b;13&#x0005d;</xref>. The N-terminal bHLH and PAS domain of HIF-1&#x003b1; and HIF-1&#x003b2; mediates heterodimerization and DNA binding <xref ref-type="bibr" rid="pone.0007332-Wang2">&#x0005b;14&#x0005d;</xref>. The cellular HIF-1&#x003b1; protein level is tightly regulated by oxygen. During normoxia HIF-1&#x003b1; is continuously hydroxylated by prolyl hydroxylases (PHD1-3), which, in turn recruits the VCB-Cul2 (von Hippel-Lindau protein (pVHL), Elongin B/C, Cullin2) E3 ubiquitin ligase complex <xref ref-type="bibr" rid="pone.0007332-Bruick1">&#x0005b;15&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007332-Maxwell1">&#x0005b;18&#x0005d;</xref>. VCB-Cul2 ubiquitinates HIF-1&#x003b1; and thereby targets it for 26S proteasomal degradation. HIF-1&#x003b1; is hydroxylated at conserved proline residues (402 and 564) located within the oxygen-dependent degradation domain (ODDD). Under hypoxic conditions, hydroxylase activities of PHDs are attenuated, resulting in HIF-1&#x003b1; stabilization and eventually the formation of active HIF-1 that regulate gene expression of HIF-1 target genes by binding to hypoxia responsive elements (HREs) <xref ref-type="bibr" rid="pone.0007332-Wang2">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007332-Pugh1">&#x0005b;19&#x0005d;</xref>.</p><p>Although HIF-1 is generally regulated by pVHL, it has become apparent that more pathways are involved in the regulation of basal HIF-1&#x003b1; levels in an oxygen- and pVHL-independent manner (reviewed in <xref ref-type="bibr" rid="pone.0007332-Liu1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007332-vandeSluis2">&#x0005b;21&#x0005d;</xref>). Recent studies showed that the heatshock protein 90&#x003b2; (HSP90&#x003b2;) binds HIF-1&#x003b1; and is necessary for proper maturation and stabilization of HIF-1&#x003b1; under normoxic and hypoxic conditions. HSP90&#x003b2; is a molecular chaperone that is involved in many different cellular processes and contributes to post-translation maturation and folding of client proteins (reviewed by <xref ref-type="bibr" rid="pone.0007332-Picard1">&#x0005b;22&#x0005d;</xref>). HSP90 inhibitors, e.g. geldanamycin or 17-Allylamino-17-demethoxygeldanamycin (17-AAG), both induce ubiquitin-independent and ubiquitin-dependent degradation of HIF-&#x003b1; independent of pVHL <xref ref-type="bibr" rid="pone.0007332-Fath1">&#x0005b;23&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007332-Minet1">&#x0005b;28&#x0005d;</xref>.</p><p>In this study, we further characterized the role of COMMD1 in HIF-1&#x003b1; proteolysis and demonstrated that COMMD1 regulates HIF-1&#x003b1; stability in a pVHL/O<sub>2</sub> and ubiquitin-independent manner by competing with HSP90&#x003b2; for binding to HIF-1&#x003b1;. Our findings suggest that COMMD1 is associated with the HSP90&#x003b2;/HSP70 chaperone regulatory axis in regulating HIF-1 pathway activity, and explain why loss of COMMD1 attenuates HIF-1&#x003b1; proteolysis <italic>in vivo</italic>.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>COMMD1 mediates HIF-1&#x003b1; protein stability</title><p>We previously demonstrated that COMMD1 physically interacts with HIF-1&#x003b1; and that loss of COMMD1 is associated with increased HIF-1&#x003b1; protein stability <italic>in vivo</italic> and <italic>in vitro</italic>. To further define the role of COMMD1 in HIF-1&#x003b1; regulation, we generated stable HeLa COMMD1 knock down cells by transfection of pSuper&#x02013;shRNA, as described previously <xref ref-type="bibr" rid="pone.0007332-vandeSluis1">&#x0005b;11&#x0005d;</xref>. This cell line and a control HeLa cell line were cultured for 18 h at 1&#x00025; O<sub>2</sub>, which resulted in comparable HIF-1&#x003b1; protein stabilization in both cell lines (<xref ref-type="fig" rid="pone-0007332-g001">Figure 1A</xref>). Upon reoxygenation (ambient O<sub>2</sub>), HIF-1&#x003b1; levels decreased in both cell lines but in COMMD1 knockdown cells the rate of HIF-1&#x003b1; degradation was markedly reduced. After 5 min of normoxic exposure, high HIF-1&#x003b1; level was still seen in COMMD1 knockdown cells, whereas HIF-1&#x003b1; was almost undetectable in the control cell line. In both cells lines, higher molecular weight species of HIF-1&#x003b1; were detected by immunoblotting that appeared more abundant in reoxygenated COMMD1-silenced cells. The identity of these higher molecular weight band is unknown at present but may represent posttranslational modification such as ubiquitination. These findings are in agreement with a role for COMMD1 in HIF-1&#x003b1; degradation as observed in HEK 293T cells <xref ref-type="bibr" rid="pone.0007332-vandeSluis1">&#x0005b;11&#x0005d;</xref></p><fig id="pone-0007332-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007332.g001</object-id><label>Figure 1</label><caption><title>COMMD1 mediates HIF-1&#x003b1; protein stability.</title><p>(A) The stability of HIF-1&#x003b1; protein was determined in HeLa COMMD1 knockdown (KD) and control (EV) cells by immunoblotting. After hypoxia (1&#x00025; O<sub>2</sub>) for 8 hours the cells were reoxygenized (21&#x00025; O<sub>2</sub>) for the indicated time prior to cell lysis. Post-translational modified HIF-1&#x003b1;, can be seen as high-molecular mass-proteins detected by anti-HIF-1&#x003b1; antibody indicated with asterisks. &#x003b2;-actin expression was used as a loading. (B) The maturation/stability of HIF-1&#x003b1; protein, was determined in HeLa COMMD1 knockdown (KD) and control cells (EV) by immunoblotting. After culturing the cells under normoxic conditions (21&#x00025; O<sub>2</sub>) cells were exposed to 1&#x00025; O<sub>2</sub> for the indicated times. HSP90&#x003b2; expression was determined and &#x003b2;-actin expression was used as a loading control. This experiment was repeated three times with similar results.</p></caption><graphic xlink:href="pone.0007332.g001"/></fig><p>Recently we suggested that COMMD1 promotes the proteolysis of newly synthesized and incorrectly folded ATP7B proteins <xref ref-type="bibr" rid="pone.0007332-deBie1">&#x0005b;8&#x0005d;</xref>. To investigate whether COMMD1 is also involved in the stability of newly synthesized HIF-1&#x003b1;, we studied the dynamics of HIF-1&#x003b1; maturation at several time-points after oxygen deprivation in control or COMMD1 knockdown cells. These cells, cultured under normoxia (21&#x00025; O<sub>2</sub>), were exposed to hypoxia (1&#x00025; O<sub>2</sub>) after removal of the culture medium to obtain rapid deoxygenation. Upon oxygen deprivation, the levels of HIF-1&#x003b1; rapidly increased in both cell lines in a time-dependent fashion (<xref ref-type="fig" rid="pone-0007332-g001">Figure 1B</xref>). However, HIF-1&#x003b1; level in COMMD1 silenced cells were markedly higher at all time-points, than in control cells (<xref ref-type="fig" rid="pone-0007332-g001">Figure 1B</xref>). Similar results were obtained with silenced COMMD1 HEK 293T cells (data not shown). Altogether, these data indicate that COMMD1 controls the protein degradation and maturation of HIF-1&#x003b1;.</p></sec><sec id="s2b"><title>COMMD1 competes with HSP90&#x003b2; for binding to HIF-1&#x003b1;</title><p>We recently showed that COMMD1 directly binds to the N-terminal region of HIF-1&#x003b1; and competes with HIF-1&#x003b2; for binding to HIF-1&#x003b1; (van de Sluis et al., submitted). The heat shock protein HSP90&#x003b2; binds also to this region of HIF-1&#x003b1; and is essential for the stability and maturation of HIF-1&#x003b1; protein <xref ref-type="bibr" rid="pone.0007332-Kong1">&#x0005b;25&#x0005d;</xref>. Since both proteins bind to same region, we examined the interaction between HIF-1&#x003b1; and COMMD1 in relation to HSP90&#x003b2; levels. COMMD1-Ha and Flag-HIF-1&#x003b1; were transfected in HEK 293T cells in the presence of increasing amounts of Ha-HSP90&#x003b2;. COMMD1-Ha co-immunoprecipitated with HIF-1&#x003b1; under all conditions, but the level of COMMD1-HIF-1&#x003b1; binding gradually decreased with increasing HSP90&#x003b2; levels (<xref ref-type="fig" rid="pone-0007332-g002">Figure 2A</xref>). The competition between HSP90&#x003b2; and COMMD1 for HIF binding could be reversed when culturing in the presence of an HSP90 specific inhibitor, 17-Allylamino-17-demethoxygeldanamycin (17-AAG). Moreover, the interaction between COMMD1 and HIF-1&#x003b1; was enhanced after 17-AAG treatment compared to mock treated cells or cells not transfected with HSP90&#x003b2;. This interaction was even more pronounced when proteasomal degradation was blocked (<xref ref-type="fig" rid="pone-0007332-g002">Figure 2B</xref>). Consistent with a competition model, we found that overexpression of COMMD1 decreased HSP90&#x003b2; binding to HIF-1&#x003b1; (<xref ref-type="fig" rid="pone-0007332-g002">Figure 2C</xref>). To address whether COMMD1/HSP90 mediated HIF-1&#x003b1; degradation was dependent on pVHL we used a hydroxy-prolyl HIF-1&#x003b1; mutant (P402A/P564A), which is not targeted for pVHL-mediated proteasomal degradation. HSP90&#x003b2; also decreased the binding of COMMD1 with the hydroxy-prolyl HIF-1&#x003b1; mutant and was completely abrogated in the presence of 17-AAG (<xref ref-type="fig" rid="pone-0007332-g002">Figure 2D</xref>) indicating that the effect of COMMD1 was independent of proly-hydroxylation and pVHL binding to HIF-1&#x003b1;. These results show that the binding of COMMD1 to HIF-1&#x003b1; is in competition with active HSP90&#x003b2;, in a dose-dependent manner.</p><fig id="pone-0007332-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007332.g002</object-id><label>Figure 2</label><caption><title>HSP90&#x003b2; competes with COMMD1 for binding to HIF-1&#x003b1;.</title><p>(A). HEK 293T cells were transfected with cDNA constructs encoding COMMD1-Ha, Flag-HIF-1&#x003b1;, or Ha-HSP90&#x003b2; with increase amounts of plasmid DNA as indicated. Whole cell lysates were immunoprecipitated with anti-Flag antibody and subjected to Western Blot analysis. (B) Anti-Flag immunprecipitations using HEK 293T whole cells lysates expressing Ha-HSP90&#x003b2;, COMMD1-Ha, Flag-HIF-1&#x003b1;. Prior to cell lysis and immunoprecipitation cells were treated with vehicle, 17-AAG (2 &#x000b5;M, 8 hr), or MG132 (5 &#x000b5;M, 8 hr) as indicated. (C) Cells were cotransfected with Ha-HSP90&#x003b2;, COMMD1-Ha, Flag-HIF-1&#x003b1;. Whole cell lysates were subjected to immunprecipation with anti-Flag antibody. Bands were quantified by densitometry using Quantity One (Bio-Rad) to calculate the quantity of the ratio of precipitated HSP90&#x003b2; relative to the input levels. The percentage of precipitated HSP90&#x003b2; is indicated (D) HEK 293T whole cells lysates expressing Ha-HSP90&#x003b2;, COMMD1-Ha, Flag-HIF-1&#x003b1; (P402A/P564A) were used for immunprecipation with anti-Flag antibody. Prior to cell lysis and immunoprecipitation cells were treated with vehicle or 17-AAG (2 &#x000b5;M, 8 hr). All data represent at least two experiments with comparable results.</p></caption><graphic xlink:href="pone.0007332.g002"/></fig></sec><sec id="s2c"><title>COMMD1 promotes HIF-1&#x003b1; degradation in an ubiquitin independent manner</title><p>Since HSP90&#x003b2; regulates the HIF-1&#x003b1; protein stability in a pVHL-independent manner we investigated the stability of the hydroxy-prolyl HIF-1&#x003b1; mutant (P402A/P564A) in HEK 293T cells stably overexpressing COMMD1-Flag (<xref ref-type="fig" rid="pone-0007332-g003">Figure 3A</xref>). HEK-293T-COMMD1 cells expressed approximately 3.5-fold higher COMMD1 levels than control cells. The endogenous COMMD1 protein was repressed in HEK293-COMMD1-Flag cells (<xref ref-type="fig" rid="pone-0007332-g003">Figure 3A</xref>), a phenomenon also observed and described by others <xref ref-type="bibr" rid="pone.0007332-Maine2">&#x0005b;3&#x0005d;</xref>. We expressed Flag-HIF-1&#x003b1; (P402A/P564A) in both cell lines in the presence or absence of 17-AAG. After adding cyclohexamide (CHX), to block new protein synthesis, we assessed whether COMMD1 overexpression resulted in a decrease of HIF-1&#x003b1; stability. No clear difference in HIF-1&#x003b1; stability could be detected between COMMD1 overexpression and control HEK 293T cells in the absence of 17-AAG, whereas the half-life of HIF-1&#x003b1; was markedly reduced in control cells and COMMD1 overexpression cells treated with 17-AAG (<xref ref-type="fig" rid="pone-0007332-g003">Figure 3B</xref>). However, inhibition of HSP90&#x003b2; in COMMD1 overexpressing cells significantly decreased the half-life of HIF-1&#x003b1; compared to control cells (<xref ref-type="fig" rid="pone-0007332-g003">Figure 3B</xref>). Next, we studied whether COMMD1 promotes the degradation of HIF-1&#x003b1; in an ubiquitin-independent manner by studying the expression of endogenous HIF-1&#x003b1; in a Chinese hamster ovary (CHO) cell line (Ts20), which contains thermolabile ubiquitin activation enzyme E1 <xref ref-type="bibr" rid="pone.0007332-Kulka1">&#x0005b;29&#x0005d;</xref>. At non-permissive temperature (39&#x000b0;C) the ubiquitin conjugation is dysfunctional and leads to HIF-1&#x003b1; stability in an oxygen-independent manner (<xref ref-type="fig" rid="pone-0007332-g003">Figure 3C</xref>). Under these conditions HIF-1&#x003b1; levels were clearly reduced when HSP90&#x003b2; activity was inhibited. Interestingly, overexpression of COMMD1 together with 17-AAG treatment considerably decreased endogenous HIF-1&#x003b1; levels in the absence of ubiquitination (<xref ref-type="fig" rid="pone-0007332-g003">Figure 3C</xref>). These data further demonstrate that COMMD1 mediates HIF-1&#x003b1; stability in concert with HSP90&#x003b2; activity in a manner independent pVHL-mediated polyubiquitination.</p><fig id="pone-0007332-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007332.g003</object-id><label>Figure 3</label><caption><title>COMMD1 increased HIF-1&#x003b1; proteolysis in an HSP90-dependent but ubiquitin independent manner.</title><p>HEK 293T stably overexpressing COMMD1-Flag (OV) and control cells (EV) (A) were transfected with Flag-HIF-1&#x003b1; (P402A/P564A). Cells were untreated or treated with 17-AAG (2 &#x000b5;M) and CHX (40 &#x000b5;g/ml) was added to the cells. HIF-1&#x003b1; levels were determined by Western Blot analysis. Bands were quantified by densitometry using Quantity One (Bio-Rad) to calculate the half-life values (T1/2) of HIF-1&#x003b1; (P402A/P564A). For each sample, mean values&#x000b1;SEM are shown (n&#x0200a;&#x0003d;&#x0200a;3), significant difference were determined using a Student <italic>t</italic>-test, p&#x0200a;&#x0003d;&#x0200a;0.0438 (C) Ts20 cells, containing thermolabile ubiquitin activation enzyme E1, were transfected with empty vector or COMMD1-flag. Cells were cultured under permissive temperature (30&#x000b0;C) or nonpermissive temperature (39&#x000b0;C) for 10 hr. Cells were treated with vehicle or 17-AAG for 8 hr prior to cell lysis and western blot analysis. All data represent three experiments with comparable results.</p></caption><graphic xlink:href="pone.0007332.g003"/></fig></sec><sec id="s2d"><title>COMMD1 forms a tripartite complex with HSP70 and HIF-1&#x003b1;</title><p>Heat shock protein HSP70 also binds to HIF-1&#x003b1; in an HSP90&#x003b2;-dependent manner and facilitates the proteolysis of misfolded and immature HIF-1&#x003b1; <xref ref-type="bibr" rid="pone.0007332-Kong1">&#x0005b;25&#x0005d;</xref> in a manner similar seen for COMMD1 (<xref ref-type="fig" rid="pone-0007332-g002">Figure 2B,D</xref>). We therefore hypothesized that COMMD1 may act as a &#x02018;scaffold&#x02019; protein involved degradation of HIF-1&#x003b1; together with HSP70. First we studied the interaction between HSP70 and HIF-1&#x003b1; under normal conditions and after attenuating HSP90 activity. Blocking HSP90 clearly increased the binding between HSP70 and HIF-1&#x003b1; (<xref ref-type="fig" rid="pone-0007332-g004">Figure 4A</xref>). Second, we investigated whether HSP70 and COMMD1 form a protein complex with HIF-1&#x003b1;. To address this we sequentially precipitated Flag-HIF-1&#x003b1; from cells, in which we co-expressed Flag-HIF-1&#x003b1;, HSP70 and COMMD1-Ha. Transfected cells were treated with 17-AAG to block HSP90&#x003b2; activity prior to cell lysis. Flag-precipitates were eluted with Flag-peptide and subsequently re-precipitated with anti-Ha to enrich for COMMD1 containing immunocomplexes. As demonstrated in <xref ref-type="fig" rid="pone-0007332-g004">Figure 4B</xref>, HSP70 could be found in complex with COMMD1 in cells expressing HIF-1&#x003b1;. To delineate whether COMMD1 is associated with HSP70, HSP70 was immunoprecipitated from HEK 293T cell lysates expressing HSP70-V5 and COMMD1-Ha. COMMD1 was clearly present in HSP70-immunoprecipates (<xref ref-type="fig" rid="pone-0007332-g004">Figure 4C</xref>). These data indicate that COMMD1 can form with HSP70 a tripartite complex with HIF-1&#x003b1;.</p><fig id="pone-0007332-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007332.g004</object-id><label>Figure 4</label><caption><title>COMMD1 forms a tripartite complex with HSP70 and HIF-1&#x003b1;.</title><p>(<bold>&#x00391;</bold>) HEK 293T whole cells lysates expressing HSP70 and Flag-HIF-1&#x003b1; were used for anti-Flag immunprecipitation. Prior to cell lysis cells were treated with vehicle or 17-AAG (2 &#x000b5;M, 8 hr) as indicated. (B) HEK 293T cells were transfected with plasmids encoding HSP70, COMMD1-Ha and Flag-HIF-1&#x003b1;. Lysates of cells, which were treated with 17-AAG (2 &#x000b5;M, 8 hr), were used for sequential immunoprecipitation. Anti-Flag precipitates were eluted with Flag-peptides and eluates were used for immunoprecipitation with anti-HA antibody. Whole cell lysates, and immunoprecipitates were subjected to Western Blot analysis. (C) Using anti-V5 antibody HSP70 was immunoprecipitated from HEK 293T cell lystates expressing HSP70-V5 and COMMD1-Ha. Whole cell lysates, and precipitates were analyzed by SDS-PAGE and immunoblotting as indicated.</p></caption><graphic xlink:href="pone.0007332.g004"/></fig></sec></sec><sec id="s3"><title>Discussion</title><p>COMMD1 has been recognized as a protein that plays an important role in wide range of biological processes, including copper metabolism, NF-&#x003ba;B signaling and sodium transport (reviewed in <xref ref-type="bibr" rid="pone.0007332-vandeSluis2">&#x0005b;21&#x0005d;</xref>). We recently identified COMMD1 as a novel protein regulating HIF-1 signaling as embryos deficient for <italic>Commd1</italic> display upregulation of HIF-1 target genes with corresponding increased HIF-1&#x003b1; protein stability <xref ref-type="bibr" rid="pone.0007332-vandeSluis1">&#x0005b;11&#x0005d;</xref>. In this study, we further characterized the mechanism of COMMD1 in HIF-1&#x003b1; regulation and demonstrated that COMMD1 competes with HSP90&#x003b2; for binding to HIF-1&#x003b1; to facilitate HIF-1&#x003b1; degradation. Overexpression of COMMD1 enhances the protein degradation of HIF-1&#x003b1; in an HSP90-dependent but pVHL/O<sub>2</sub> and ubiquitin-independent manner (<xref ref-type="fig" rid="pone-0007332-g003">Figure 3</xref>). Previous studies reported that upon HSP90 inhibition, a protein complex consisting of HSP70 and HIF-1&#x003b1; is formed to facilitate 20S proteasomal degradation in an ubiquitin-independent fashion <xref ref-type="bibr" rid="pone.0007332-Kong1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007332-Zhou1">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007332-Kong2">&#x0005b;31&#x0005d;</xref>. Here we showed that COMMD1 is in complex with HSP70/HIF-1&#x003b1; suggesting that COMMD1 acts in concert with HSP70 to facilitate proteolysis of HIF-1&#x003b1; in an HSP90-dependent manner.</p><p>The effect of COMMD1 on HIF-1&#x003b1; stability is also evident during the early transitions between hypoxia and normoxia and vice versa. In cells reoxygenation in the absence COMMD1 results in a delay in the rate of HIF-1&#x003b1; degradation (<xref ref-type="fig" rid="pone-0007332-g001">Figure 1A</xref>). It is well established that under normal oxygen conditions, HIF-1&#x003b1; levels are downregulated by polyubiquitination and proteosomal degradation (18). We therefore hypothesize that the higher molecular weight protein, detected by the HIF-1&#x003b1; antibody, represents polyubiquitinated-HIF-1&#x003b1; species. We have previously observed the same HIF-1&#x003b1; pattern in HEK 293T COMMD1 deficient cells upon reoxygenation (<xref ref-type="bibr" rid="pone.0007332-vandeSluis1">&#x0005b;11&#x0005d;</xref>). The persistence of polyubiquitinated HIF-1&#x003b1; in COMMD1 deficient cells may suggest that COMMD1 does not affect HIF-1&#x003b1; polyubiquitination per se but assists the proteasomal degradation of HIF-1&#x003b1;. This could also explain why HIF-1 transcriptional activity is higher in the absence of COMMD1 (11). Together with our observation that COMMD1 interacts with the 20S proteasome (supplemental <xref ref-type="supplementary-material" rid="pone.0007332.s001">Figure S1</xref>) we hypothesize that COMMD1 may escort HIF-1&#x003b1; protein to the proteasome. Furthermore, the increased interaction between COMMD1 and 20S after blocking proteasomal degradation, supports a more general role for COMMD1 in the 20S proteasome. Ubiquitin-independent degradation of HIF-1&#x003b1; directly by the 20S proteosome has also been reported by others and seems to be involved in regulating constitutive degradation of HIF-1&#x003b1; during hypoxia <xref ref-type="bibr" rid="pone.0007332-Kong2">&#x0005b;31&#x0005d;</xref>. While HIF-1&#x003b1; can interact with the 20S proteasome subunit PMSA7 (&#x003b1;-4 subunit), it is unknown yet whether this is a direct process or regulated by other proteins <xref ref-type="bibr" rid="pone.0007332-Cho1">&#x0005b;32&#x0005d;</xref>. Although more studies are needed, these data shed light on a novel pathway of HIF-1&#x003b1; regulation by the 20S proteasome in an O<sub>2</sub> and ubiquitin-independent manner.</p><p>A competition with HSP90&#x003b2; for binding to HIF-1&#x003b1; was also reported for Receptor for activated protein kinase C 1 (RACK1) <xref ref-type="bibr" rid="pone.0007332-Liu2">&#x0005b;26&#x0005d;</xref>. Similar as for COMMD1, RACK1 reduces HIF-1 transcriptional activity and mediates HIF-1&#x003b1; protein degradation independent of O<sub>2</sub>-and pVHL. However, in constrast to COMMD1, RACK1 recruits the Elongin-C/B ubiquitin ligase complex and regulates HIF-1&#x003b1; stability in an ubiquitin-dependent fashion. Importantly, we found no effect of COMMD1 on RACK1-HIF-1&#x003b1; binding (supplemental <xref ref-type="supplementary-material" rid="pone.0007332.s002">Figure S2</xref>) suggesting that COMMD1 does not compete with RACK1 for binding to HIF-1&#x003b1; and regulates HIF in a distinct manner.</p><p>Interestingly, COMMD1 also promotes the proteolysis of the copper transporting p-type ATPase ATP7B <xref ref-type="bibr" rid="pone.0007332-deBie1">&#x0005b;8&#x0005d;</xref>. This study established a stronger binding between COMMD1 and ATP7B mutants that are associated with mis-localization and protein instability compared to wild-type ATP7B. It has been postulated that COMMD1 is engaged in the quality control and protein folding of newly synthesized ATP7B. Although recent data demonstrated interaction between ATP7B and the molecular chaperones HSP70 and HSP90&#x003b2; (unpublished data, P. van den Berghe and L.W. Klomp) the mechanism of COMMD1 in regulating ATP7B degradation is largely unknown. Further studies are needed to reveal whether COMMD1 also cooperates with HSP70 and HSP90&#x003b2; to regulate the structural integrity of ATP7B by assisting the proteolysis of misfolded ATP7B proteins</p><p>Taken together, this study demonstrates that COMMD1, in complex with HSP70, facilitates the proteasomal degradation of HIF-1&#x003b1; in an HSP90-dependent and ubiquitin independent manner (<xref ref-type="fig" rid="pone-0007332-g005">Figure 5</xref>). In addition, these findings highlight a potentially novel role of COMMD1 protein in escorting client proteins to the proteasome. Importantly, hypoxia is a hallmark of solid cancers and HIF-1 activity correlates with a poor prognosis in many cancers <xref ref-type="bibr" rid="pone.0007332-Bos1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007332-Pouyssegur1">&#x0005b;34&#x0005d;</xref>. Currently, HSP90 inhibitiors (e.g. 17-AAG) are being tested in clinical trials as potential anti-cancer agents <xref ref-type="bibr" rid="pone.0007332-Semenza2">&#x0005b;35&#x0005d;</xref>. Therefore, further elucidation of the molecular mechanism of HSP90-dependent proteolysis of proteins may reveal additional opportunities for modulation of HIF-1 activity in human disease, including cancer.</p><fig id="pone-0007332-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007332.g005</object-id><label>Figure 5</label><caption><title>Schematic representation of the mechanism of COMMD1-associated HIF-1&#x003b1; degradation.</title><p>Under normoxic conditions, newly synthesized HIF-1&#x003b1; binds to HSP70 and HSP90 for proper maturation, but it is immediately degraded by the 26S proteasome after it is hydroxylated and ubiquitinated in a pVHL dependent process. Under hypoxic conditions, HIF-1&#x003b1; is not subjected to hydroxyl- and ubiquitin-dependent degradation and heterodimerizes with HIF-1&#x003b2;, and binds to hypoxia response element (HRE) containing promoters in target genes. Upon reoxygenation HIF-1&#x003b1; is ubiquitinated by pVHL, and COMMD1 is bound to HIF-1&#x003b1; to facilitate proteasomal degradation. Inactivation of HSP90 (e.g. using 17-AAG or Geldanamycin) leads to incorrect folding of HIF-1&#x003b1; and the formation of a heterocomplex with HSP70 and COMMD1, and subsequently degradation by the 20S proteasome. Altogether, in this study we suggest that COMMD1 facilitates the proteasomal degradation of HIF-1&#x003b1; after reoxygenation or HSP90 inhibition independent of posttranslational modification by ubiquitin.</p></caption><graphic xlink:href="pone.0007332.g005"/></fig></sec><sec id="s4" sec-type="materials|methods"><title>Materials and Methods</title><sec id="s4a"><title>Construction of expression constructs</title><p>Flag-HIF-1&#x003b1; construct was previously described <xref ref-type="bibr" rid="pone.0007332-vandeSluis1">&#x0005b;11&#x0005d;</xref>. Mutants for full length HIF-1&#x003b1; P402A/P564A were generated using the QuickChange&#x000ae; XL Site directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol, using the primers P402A forward <named-content content-type="gene">5&#x02032;-CTTTAACTTTGCTGGCCGCAGCCGCTGGAGACAC-3&#x02032;</named-content> and P402A reverse <named-content content-type="gene">5&#x02032;-GTGTCTCCAGCGGCTGCGGCCAGCAAAGTTAAAG-3&#x02032;</named-content> and P564A forward <named-content content-type="gene">5&#x02032;-CTTGGAGATGTTAGCTGCCTATATCCCAATGGATG-3&#x02032;</named-content> and P564A reverse <named-content content-type="gene">5-CATCCATTGGGATATAGGCAGCTAACATCTCCAAG-3&#x02032;</named-content>. pcDNA3.1-Ha-HSP90&#x003b2; was kindly provided by Dr. D. Manor (Case Western Reserve University, Cleveland, OH, USA), pcDNA3.1-HSP70 and pcDNA5/FRT/TO-HSP70-V5 was kindly provided by Dr. H. Kampinga (Department of Cell Biology, UMC Groningen, the Netherlands). A plasmid containing the RACK1 cDNA was kindly provided by Dr. D. Qian and recloned in p3xFLAG-CMV10.</p></sec><sec id="s4b"><title>Cell culture, transfections, co-immunoprecipitation, and immunoblotting</title><p>HEK 293T and HeLa cells were cultured in Dulbecco's modified Eagle medium supplemented with 10&#x00025; fetal bovine serum, penicillin-streptomycin, L-glutamine. Cells were cultured at 5&#x00025; CO<sub>2</sub>, 21&#x00025; O<sub>2</sub> for normoxia and 1&#x00025; O<sub>2</sub> for hypoxia in an Invivo<sub>2</sub> Hypoxia Workstation 1000 (Biotrace International, UK) at 37&#x000b0;C. Stable HeLa COMMD1 knockdown cells were generated as previously described <xref ref-type="bibr" rid="pone.0007332-vandeSluis1">&#x0005b;11&#x0005d;</xref>. Monoclonal were selected by culturing on a medium supplemented with 1 &#x000b5;g/ml puromycin (Sigma-Aldrich, Zwijndrecht, the Netherlands). Ts20 cells were cultured in MEM Alpha medium&#x0002b;GlutaMAX, supplemented with 10&#x00025; fetal bovine serum, penicillin-streptomycin. Ts20 cells were cultured at 5&#x00025; CO<sub>2</sub>, 21&#x00025; O<sub>2</sub> at 30&#x000b0;C.</p><p>Linear polyethylenimine (P-PEI, Polysciences Inc, Warrington, PA, USA) was used for tranfections. After transfection, cells were lysed in lysis buffer (0.4 M NaCl, 0.1&#x00025; NP-40, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA) supplemented with 1 mM Na<sub>3</sub>VO<sub>4</sub>, protease inhibitors (Roche, Basle, Switzerland), and 10 mM dithiothreitol. In several experiments MG132 (5 &#x000b5;M, 8 hr) was used to prevent proteasomal degradation of HIF-1&#x003b1; and to attain constant HIF-1&#x003b1; levels. HSP70-V5 expression was achieved by adding doxycycline after transfection. Cell line extracts representing 30 &#x000b5;g protein were transferred onto Hybond-P membranes as explained previously <xref ref-type="bibr" rid="pone.0007332-vandeSluis1">&#x0005b;11&#x0005d;</xref>. Immunoblots were probed with anti-COMMD1 antiserum (1&#x02236;5,000) <xref ref-type="bibr" rid="pone.0007332-Klomp1">&#x0005b;6&#x0005d;</xref>, anti-Flag (F1804; Sigma-Aldrich), anti-Ha (clone HA-7, Sigma-Aldrich), anti-&#x003b2;-actin monoclonal antibodies (clone AC-74; Sigma-Aldrich), anti-HIF-1&#x003b1; (clone 54; BD Bioscience, Alphen aan de Rijn, the Netherlands), anti-HSP70 (sc-1060, Santa Cruz), anti-HSP90&#x003b2; (SPA-843, Stressgen, Victoria, British Columbia, Canada).</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0007332.s001"><label>Figure S1</label><caption><p>COMMD1 interacts with 20S proteasome. Glutathione-sepharose precipitations using cell lysates of HEK 293T transfected with GST or COMMD1-GST. Prior cell lysis, cells were untreated (mock treated, DMSO) or treated with MG132 (5 &#x000b5;M, 8 hr) as indicated. Proteins were detected with anti-GST or anti-20S &#x003b1;-subunit (&#x003b1;1, 2 ,3 ,5 ,6 &#x00026; 7, Biomol, clone MCP231) as indicated. Input designates direct analysis of cell lysates.</p><p>(0.34 MB PDF)</p></caption><media xlink:href="pone.0007332.s001.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007332.s002"><label>Figure S2</label><caption><p>COMMD1 does not compete with RACK1 for binding to the N-terminus of HIF-1&#x003b1;. Glutathione-sepharose precipitations using cell lysates of HEK 293T transfected with GST or GST-HIF-1&#x003b1; (1&#x02013;300), RACK1-Flag or COMMD1-Ha with increased amounts of plasmid as indicated. Precipitates were washed and separated by SDS-PAGE and immunoblotted as indicated. Input designates direct analysis of cell lysates.</p><p>(5.03 MB PDF)</p></caption><media xlink:href="pone.0007332.s002.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Rene Bernards (Netherlands Cancer Institute), Marten Hofker (UMC Groningen) and Erik Danen (Leiden University Medical Center) for their critical comments on the mansucript. We thank Jackie Senior for improving the manuscript.</p></ack><ref-list><title>References</title><ref id="pone.0007332-Burstein1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>E</given-names></name><name><surname>Hoberg</surname><given-names>JE</given-names></name><name><surname>Wilkinson</surname><given-names>AS</given-names></name><name><surname>Rumble</surname><given-names>JM</given-names></name><name><surname>Csomos</surname><given-names>RA</given-names></name><etal/></person-group><year>2005</year><article-title>COMMD proteins, a novel family of structural and functional homologs of MURR1.</article-title><source>J Biol Chem</source><volume>280</volume><fpage>22222</fpage><lpage>22232</lpage><pub-id pub-id-type="pmid">15799966</pub-id></mixed-citation></ref><ref id="pone.0007332-Maine1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maine</surname><given-names>GN</given-names></name><name><surname>Burstein</surname><given-names>E</given-names></name></person-group><year>2007</year><article-title>COMMD proteins: COMMing to the scene.</article-title><source>Cell Mol Life Sci</source><volume>64</volume><fpage>1997</fpage><lpage>2005</lpage><pub-id pub-id-type="pmid">17497243</pub-id></mixed-citation></ref><ref id="pone.0007332-Maine2"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maine</surname><given-names>GN</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Muller</surname><given-names>PA</given-names></name><name><surname>Komarck</surname><given-names>CM</given-names></name><name><surname>Klomp</surname><given-names>LW</given-names></name><etal/></person-group><year>2009</year><article-title>COMMD1 expression is controlled by critical residues that determine XIAP binding.</article-title><source>Biochem J</source><volume>417</volume><fpage>601</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">18795889</pub-id></mixed-citation></ref><ref id="pone.0007332-Muller1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>PA</given-names></name><name><surname>van de Sluis</surname><given-names>B</given-names></name><name><surname>Groot</surname><given-names>AJ</given-names></name><name><surname>Verbeek</surname><given-names>D</given-names></name><name><surname>Vonk</surname><given-names>WI</given-names></name><etal/></person-group><year>2009</year><article-title>Nuclear-cytosolic transport of COMMD1 regulates NF-kappaB and HIF-1 activity.</article-title><source>Traffic</source></mixed-citation></ref><ref id="pone.0007332-Maine3"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maine</surname><given-names>GN</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Komarck</surname><given-names>CM</given-names></name><name><surname>Burstein</surname><given-names>E</given-names></name></person-group><year>2007</year><article-title>COMMD1 promotes the ubiquitination of NF-kappaB subunits through a cullin-containing ubiquitin ligase.</article-title><source>Embo J</source><volume>26</volume><fpage>436</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">17183367</pub-id></mixed-citation></ref><ref id="pone.0007332-Klomp1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klomp</surname><given-names>AE</given-names></name><name><surname>van de Sluis</surname><given-names>B</given-names></name><name><surname>Klomp</surname><given-names>LW</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name></person-group><year>2003</year><article-title>The ubiquitously expressed MURR1 protein is absent in canine copper toxicosis.</article-title><source>J Hepatol</source><volume>39</volume><fpage>703</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">14568250</pub-id></mixed-citation></ref><ref id="pone.0007332-vanDeSluis1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van De Sluis</surname><given-names>B</given-names></name><name><surname>Rothuizen</surname><given-names>J</given-names></name><name><surname>Pearson</surname><given-names>PL</given-names></name><name><surname>van Oost</surname><given-names>BA</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name></person-group><year>2002</year><article-title>Identification of a new copper metabolism gene by positional cloning in a purebred dog population.</article-title><source>Hum Mol Genet</source><volume>11</volume><fpage>165</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">11809725</pub-id></mixed-citation></ref><ref id="pone.0007332-deBie1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bie</surname><given-names>P</given-names></name><name><surname>van de Sluis</surname><given-names>B</given-names></name><name><surname>Burstein</surname><given-names>E</given-names></name><name><surname>van de Berghe</surname><given-names>PV</given-names></name><name><surname>Muller</surname><given-names>P</given-names></name><etal/></person-group><year>2007</year><article-title>Distinct Wilson's disease mutations in ATP7B are associated with enhanced binding to COMMD1 and reduced stability of ATP7B.</article-title><source>Gastroenterology</source><volume>133</volume><fpage>1316</fpage><lpage>1326</lpage><pub-id pub-id-type="pmid">17919502</pub-id></mixed-citation></ref><ref id="pone.0007332-Tao1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>TY</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Klomp</surname><given-names>L</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Gitlin</surname><given-names>JD</given-names></name></person-group><year>2003</year><article-title>The copper toxicosis gene product Murr1 directly interacts with the Wilson disease protein.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>41593</fpage><lpage>41596</lpage><pub-id pub-id-type="pmid">12968035</pub-id></mixed-citation></ref><ref id="pone.0007332-Mao1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Gluck</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Maine</surname><given-names>GN</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><year>2009</year><article-title>GCN5 is a required cofactor for a ubiquitin ligase that targets NF-kappaB/RelA.</article-title><source>Genes Dev</source><volume>23</volume><fpage>849</fpage><lpage>861</lpage><pub-id pub-id-type="pmid">19339690</pub-id></mixed-citation></ref><ref id="pone.0007332-vandeSluis1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Sluis</surname><given-names>B</given-names></name><name><surname>Muller</surname><given-names>P</given-names></name><name><surname>Duran</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Groot</surname><given-names>AJ</given-names></name><etal/></person-group><year>2007</year><article-title>Increased activity of hypoxia-inducible factor 1 is associated with early embryonic lethality in commd1 null mice.</article-title><source>Mol Cell Biol</source><volume>27</volume><fpage>4142</fpage><lpage>4156</lpage><pub-id pub-id-type="pmid">17371845</pub-id></mixed-citation></ref><ref id="pone.0007332-Semenza1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><year>2007</year><article-title>Hypoxia-inducible factor 1 (HIF-1) pathway.</article-title><source>Sci STKE</source><volume>2007</volume><fpage>cm8</fpage><pub-id pub-id-type="pmid">17925579</pub-id></mixed-citation></ref><ref id="pone.0007332-Wang1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GL</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name><name><surname>Rue</surname><given-names>EA</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><year>1995</year><article-title>Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.</article-title><source>Proc Natl Acad Sci U S A</source><volume>92</volume><fpage>5510</fpage><lpage>5514</lpage><pub-id pub-id-type="pmid">7539918</pub-id></mixed-citation></ref><ref id="pone.0007332-Wang2"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GL</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><year>1993</year><article-title>Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia.</article-title><source>J Biol Chem</source><volume>268</volume><fpage>21513</fpage><lpage>21518</lpage><pub-id pub-id-type="pmid">8408001</pub-id></mixed-citation></ref><ref id="pone.0007332-Bruick1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruick</surname><given-names>RK</given-names></name><name><surname>McKnight</surname><given-names>SL</given-names></name></person-group><year>2001</year><article-title>A conserved family of prolyl-4-hydroxylases that modify HIF.</article-title><source>Science</source><volume>294</volume><fpage>1337</fpage><lpage>1340</lpage><pub-id pub-id-type="pmid">11598268</pub-id></mixed-citation></ref><ref id="pone.0007332-Ivan1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivan</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Valiando</surname><given-names>J</given-names></name><etal/></person-group><year>2001</year><article-title>HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.</article-title><source>Science</source><volume>292</volume><fpage>464</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">11292862</pub-id></mixed-citation></ref><ref id="pone.0007332-Jaakkola1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaakkola</surname><given-names>P</given-names></name><name><surname>Mole</surname><given-names>DR</given-names></name><name><surname>Tian</surname><given-names>YM</given-names></name><name><surname>Wilson</surname><given-names>MI</given-names></name><name><surname>Gielbert</surname><given-names>J</given-names></name><etal/></person-group><year>2001</year><article-title>Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.</article-title><source>Science</source><volume>292</volume><fpage>468</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">11292861</pub-id></mixed-citation></ref><ref id="pone.0007332-Maxwell1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maxwell</surname><given-names>PH</given-names></name><name><surname>Wiesener</surname><given-names>MS</given-names></name><name><surname>Chang</surname><given-names>GW</given-names></name><name><surname>Clifford</surname><given-names>SC</given-names></name><name><surname>Vaux</surname><given-names>EC</given-names></name><etal/></person-group><year>1999</year><article-title>The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.</article-title><source>Nature</source><volume>399</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">10353251</pub-id></mixed-citation></ref><ref id="pone.0007332-Pugh1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pugh</surname><given-names>CW</given-names></name><name><surname>Tan</surname><given-names>CC</given-names></name><name><surname>Jones</surname><given-names>RW</given-names></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name></person-group><year>1991</year><article-title>Functional analysis of an oxygen-regulated transcriptional enhancer lying 3&#x02032; to the mouse erythropoietin gene.</article-title><source>Proc Natl Acad Sci U S A</source><volume>88</volume><fpage>10553</fpage><lpage>10557</lpage><pub-id pub-id-type="pmid">1961720</pub-id></mixed-citation></ref><ref id="pone.0007332-Liu1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YV</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><year>2007</year><article-title>RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization.</article-title><source>Cell Cycle</source><volume>6</volume><fpage>656</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">17361105</pub-id></mixed-citation></ref><ref id="pone.0007332-vandeSluis2"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Sluis</surname><given-names>B</given-names></name><name><surname>Groot</surname><given-names>AJ</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Vooijs</surname><given-names>M</given-names></name><name><surname>Klomp</surname><given-names>LW</given-names></name></person-group><year>2007</year><article-title>COMMD1: a novel protein involved in the proteolysis of proteins.</article-title><source>Cell Cycle</source><volume>6</volume><fpage>2091</fpage><lpage>2098</lpage><pub-id pub-id-type="pmid">17786049</pub-id></mixed-citation></ref><ref id="pone.0007332-Picard1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picard</surname><given-names>D</given-names></name></person-group><year>2002</year><article-title>Heat-shock protein 90, a chaperone for folding and regulation.</article-title><source>Cell Mol Life Sci</source><volume>59</volume><fpage>1640</fpage><lpage>1648</lpage><pub-id pub-id-type="pmid">12475174</pub-id></mixed-citation></ref><ref id="pone.0007332-Fath1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fath</surname><given-names>DM</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Chou</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha.</article-title><source>J Biol Chem</source><volume>281</volume><fpage>13612</fpage><lpage>13619</lpage><pub-id pub-id-type="pmid">16543236</pub-id></mixed-citation></ref><ref id="pone.0007332-Isaacs1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaacs</surname><given-names>JS</given-names></name><name><surname>Jung</surname><given-names>YJ</given-names></name><name><surname>Mimnaugh</surname><given-names>EG</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Cuttitta</surname><given-names>F</given-names></name><etal/></person-group><year>2002</year><article-title>Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway.</article-title><source>J Biol Chem</source><volume>277</volume><fpage>29936</fpage><lpage>29944</lpage><pub-id pub-id-type="pmid">12052835</pub-id></mixed-citation></ref><ref id="pone.0007332-Kong1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Fath</surname><given-names>D</given-names></name><name><surname>Sang</surname><given-names>N</given-names></name><etal/></person-group><year>2006</year><article-title>Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha.</article-title><source>Mol Cell Biol</source><volume>26</volume><fpage>2019</fpage><lpage>2028</lpage><pub-id pub-id-type="pmid">16507982</pub-id></mixed-citation></ref><ref id="pone.0007332-Liu2"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YV</given-names></name><name><surname>Baek</surname><given-names>JH</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Diez</surname><given-names>R</given-names></name><name><surname>Cole</surname><given-names>RN</given-names></name><etal/></person-group><year>2007</year><article-title>RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha.</article-title><source>Mol Cell</source><volume>25</volume><fpage>207</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">17244529</pub-id></mixed-citation></ref><ref id="pone.0007332-Mabjeesh1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabjeesh</surname><given-names>NJ</given-names></name><name><surname>Post</surname><given-names>DE</given-names></name><name><surname>Willard</surname><given-names>MT</given-names></name><name><surname>Kaur</surname><given-names>B</given-names></name><name><surname>Van Meir</surname><given-names>EG</given-names></name><etal/></person-group><year>2002</year><article-title>Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells.</article-title><source>Cancer Res</source><volume>62</volume><fpage>2478</fpage><lpage>2482</lpage><pub-id pub-id-type="pmid">11980636</pub-id></mixed-citation></ref><ref id="pone.0007332-Minet1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minet</surname><given-names>E</given-names></name><name><surname>Mottet</surname><given-names>D</given-names></name><name><surname>Michel</surname><given-names>G</given-names></name><name><surname>Roland</surname><given-names>I</given-names></name><name><surname>Raes</surname><given-names>M</given-names></name><etal/></person-group><year>1999</year><article-title>Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction.</article-title><source>FEBS Lett</source><volume>460</volume><fpage>251</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">10544245</pub-id></mixed-citation></ref><ref id="pone.0007332-Kulka1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulka</surname><given-names>RG</given-names></name><name><surname>Raboy</surname><given-names>B</given-names></name><name><surname>Schuster</surname><given-names>R</given-names></name><name><surname>Parag</surname><given-names>HA</given-names></name><name><surname>Diamond</surname><given-names>G</given-names></name><etal/></person-group><year>1988</year><article-title>A Chinese hamster cell cycle mutant arrested at G2 phase has a temperature-sensitive ubiquitin-activating enzyme, E1.</article-title><source>J Biol Chem</source><volume>263</volume><fpage>15726</fpage><lpage>15731</lpage><pub-id pub-id-type="pmid">3049611</pub-id></mixed-citation></ref><ref id="pone.0007332-Zhou1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Schmid</surname><given-names>T</given-names></name><name><surname>Frank</surname><given-names>R</given-names></name><name><surname>Brune</surname><given-names>B</given-names></name></person-group><year>2004</year><article-title>PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation.</article-title><source>J Biol Chem</source><volume>279</volume><fpage>13506</fpage><lpage>13513</lpage><pub-id pub-id-type="pmid">14726529</pub-id></mixed-citation></ref><ref id="pone.0007332-Kong2"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Alvarez-Castelao</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Castano</surname><given-names>JG</given-names></name><name><surname>Caro</surname><given-names>J</given-names></name></person-group><year>2007</year><article-title>Constitutive/hypoxic degradation of HIF-alpha proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein.</article-title><source>J Biol Chem</source><volume>282</volume><fpage>15498</fpage><lpage>15505</lpage><pub-id pub-id-type="pmid">17403672</pub-id></mixed-citation></ref><ref id="pone.0007332-Cho1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Jeong</surname><given-names>ST</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><etal/></person-group><year>2001</year><article-title>Binding and regulation of HIF-1alpha by a subunit of the proteasome complex, PSMA7.</article-title><source>FEBS Lett</source><volume>498</volume><fpage>62</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">11389899</pub-id></mixed-citation></ref><ref id="pone.0007332-Bos1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bos</surname><given-names>R</given-names></name><name><surname>van der Groep</surname><given-names>P</given-names></name><name><surname>Greijer</surname><given-names>AE</given-names></name><name><surname>Shvarts</surname><given-names>A</given-names></name><name><surname>Meijer</surname><given-names>S</given-names></name><etal/></person-group><year>2003</year><article-title>Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.</article-title><source>Cancer</source><volume>97</volume><fpage>1573</fpage><lpage>1581</lpage><pub-id pub-id-type="pmid">12627523</pub-id></mixed-citation></ref><ref id="pone.0007332-Pouyssegur1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouyssegur</surname><given-names>J</given-names></name><name><surname>Dayan</surname><given-names>F</given-names></name><name><surname>Mazure</surname><given-names>NM</given-names></name></person-group><year>2006</year><article-title>Hypoxia signalling in cancer and approaches to enforce tumour regression.</article-title><source>Nature</source><volume>441</volume><fpage>437</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">16724055</pub-id></mixed-citation></ref><ref id="pone.0007332-Semenza2"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><year>2007</year><article-title>Evaluation of HIF-1 inhibitors as anticancer agents.</article-title><source>Drug Discov Today</source><volume>12</volume><fpage>853</fpage><lpage>859</lpage><pub-id pub-id-type="pmid">17933687</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>Financial support was obtained for the Ruskin Invivo2 Hypoxia Workstation 1000 from the Maurits Anna de Kock Foundation and Nijbakker Morra, repectively. This work was supported by the Dutch Cancer Society (UU2003&#x02013;2825) (to P.v.D., E.vd.W. and MV), and by the Dutch Organization for Scientific Research (NWO) grant number 40-00812-98-03106 (to C.W. and L.K). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>